Vincent J Wacher

Summary

Country: USA

Publications

  1. ncbi Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics
    V J Wacher
    AvMax Inc, 890 Heinz Avenue, Berkeley, California, 94710 and Department of Biopharmaceutical Sciences, University of California, San Francisco, California 94143 0446, USA
    J Pharm Sci 87:1322-30. 1998
  2. ncbi Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole
    Vincent J Wacher
    AvMax Inc, 385 Oyster Point Blvd 9A, South San Francisco, California 94080, USA
    J Pharm Sci 91:77-90. 2002
  3. ncbi Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate
    Vincent J Wacher
    AvMax Inc, South San Francisco, California 92009, USA
    J Pharmacol Exp Ther 303:308-13. 2002
  4. ncbi Minimal effect of ketoconazole on cyclosporine (SangCyA) oral absorption and first-pass metabolism in rats: evidence of a significant vehicle effect on SangCyA absorption
    Susan Wong
    AvMax Inc, South San Francisco, CA 94080, USA
    Biopharm Drug Dispos 23:53-7. 2002
  5. ncbi Pharmacokinetics of itraconazole after intravenous and oral dosing of itraconazole-cyclodextrin formulations
    Charles M Buchanan
    Eastman Chemical Company, Research Laboratories, PO Box 1972, Kingsport, Tennessee 37662, USA
    J Pharm Sci 96:3100-16. 2007
  6. ncbi Pharmacokinetics of cyclosporine pre- and post-liver transplantation
    Mary F Hebert
    University of Washington, Department of Pharmacy, H-375 Health Sciences Center, Box 357630, Seattle, WA 98195-7630, USA
    J Clin Pharmacol 43:38-42. 2003
  7. ncbi Pharmacokinetics of tamoxifen after intravenous and oral dosing of tamoxifen-hydroxybutenyl-beta-cyclodextrin formulations
    Charles M Buchanan
    Eastman Chemical Company, Research Laboratories, P O Box 1972, Kingsport, Tennessee 37662, USA
    J Pharm Sci 96:644-60. 2007
  8. ncbi Pharmacokinetics of raloxifene in male Wistar-Hannover rats: influence of complexation with hydroxybutenyl-beta-cyclodextrin
    Michael F Wempe
    Eastman Chemical Company, Kingsport, TN, USA
    Int J Pharm 346:25-37. 2008
  9. ncbi Pharmacokinetics of saquinavir after intravenous and oral dosing of saquinavir: hydroxybutenyl-beta-cyclodextrin formulations
    Charles M Buchanan
    Eastman Chemical Company, Research Laboratories, P O Box 1972, Kingsport, Tennessee 37662, USA
    Biomacromolecules 9:305-13. 2008

Collaborators

Detail Information

Publications9

  1. ncbi Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics
    V J Wacher
    AvMax Inc, 890 Heinz Avenue, Berkeley, California, 94710 and Department of Biopharmaceutical Sciences, University of California, San Francisco, California 94143 0446, USA
    J Pharm Sci 87:1322-30. 1998
    ....
  2. ncbi Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole
    Vincent J Wacher
    AvMax Inc, 385 Oyster Point Blvd 9A, South San Francisco, California 94080, USA
    J Pharm Sci 91:77-90. 2002
    ....
  3. ncbi Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate
    Vincent J Wacher
    AvMax Inc, South San Francisco, California 92009, USA
    J Pharmacol Exp Ther 303:308-13. 2002
    ..The lack of significant sirolimus transport by P-glycoprotein may, in part, explain the lack of a TPGS effect on sirolimus absorption in rats...
  4. ncbi Minimal effect of ketoconazole on cyclosporine (SangCyA) oral absorption and first-pass metabolism in rats: evidence of a significant vehicle effect on SangCyA absorption
    Susan Wong
    AvMax Inc, South San Francisco, CA 94080, USA
    Biopharm Drug Dispos 23:53-7. 2002
    ..The small effect of ketoconazole suggests that CYP3A-mediated intestinal and first-pass hepatic metabolism are minor determinants of cyclosporine oral bioavailability in rats...
  5. ncbi Pharmacokinetics of itraconazole after intravenous and oral dosing of itraconazole-cyclodextrin formulations
    Charles M Buchanan
    Eastman Chemical Company, Research Laboratories, PO Box 1972, Kingsport, Tennessee 37662, USA
    J Pharm Sci 96:3100-16. 2007
    ..No food effects were observed with the itraconazole:HBenBCD solid dosage forms. Drug/metabolite ratios were dependent upon the dosage form...
  6. ncbi Pharmacokinetics of cyclosporine pre- and post-liver transplantation
    Mary F Hebert
    University of Washington, Department of Pharmacy, H-375 Health Sciences Center, Box 357630, Seattle, WA 98195-7630, USA
    J Clin Pharmacol 43:38-42. 2003
    ..End-stage liver disease can markedly decrease hepatic clearance of CyA relative to patients with stable hepatic function post-liver tx. The degree of impairment in clearance is not consistent or predictable based on liver function tests...
  7. ncbi Pharmacokinetics of tamoxifen after intravenous and oral dosing of tamoxifen-hydroxybutenyl-beta-cyclodextrin formulations
    Charles M Buchanan
    Eastman Chemical Company, Research Laboratories, P O Box 1972, Kingsport, Tennessee 37662, USA
    J Pharm Sci 96:644-60. 2007
    ..Collectively, the data indicated that dosing of fasted animals in the morning with tamoxifen:HBenBCD formulations provided a very significant increase in tamoxifen oral bioavailability (up to 10- to 14-fold)...
  8. ncbi Pharmacokinetics of raloxifene in male Wistar-Hannover rats: influence of complexation with hydroxybutenyl-beta-cyclodextrin
    Michael F Wempe
    Eastman Chemical Company, Kingsport, TN, USA
    Int J Pharm 346:25-37. 2008
    ..Hence, these studies demonstrate that raloxifene formulations containing HBenBCD significantly increased the oral bioavailability in rats relative to formulations that did not contain HBenBCD...
  9. ncbi Pharmacokinetics of saquinavir after intravenous and oral dosing of saquinavir: hydroxybutenyl-beta-cyclodextrin formulations
    Charles M Buchanan
    Eastman Chemical Company, Research Laboratories, P O Box 1972, Kingsport, Tennessee 37662, USA
    Biomacromolecules 9:305-13. 2008
    ..Clearly, HBenBCD can significantly improve the solubility and oral bioavailability of saquinavir; however, further formulation studies are required to optimize saquinavir oral delivery using this technology...